Table 2 Proportions of patients found to have a ‘Response to Treatment’ with MultiCruzi using a threshold of −0.7 and with PCR per treatment group

From: Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay

Dosing regimen

Total Number of patients

Patients with “Response to Treatment”

Patients with PCR “Parasitological Clearance”

BZN—150 mg for 4 Weeks

30

15 (50.00%)

24 (80.00%)

BZN—300 mg for 2 Weeks

29

12 (41.38%)

23 (79.31%)

BZN—300 mg for 4 Weeks

28

13 (46.43%)

25 (89.29%)

BZN—300 mg for 8 Weeks

28

16 (57.14%)

24 (85.71%)

BZN—150 mg + E1224 for 4 Weeks

27

12 (44.44%)

23 (85.19%)

BZN—300 mg + E1224 for 8 Weeks

29

16 (55.17%)

24 (82.76%)

Placebo

30

3 (10.00%)

1 (3.33%)

  1. BZN Benznidazole; (1) BZN—150 mg for 4 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 4 weeks; (2) BZN—300 mg for 2 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 2 weeks; (3) BZN—300 mg for 4 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 4 weeks; (4) BZN—300 mg for 8 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 8 weeks; (5) BZN—150 mg + E1224 for 4 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 4 weeks plus fosravuconazole; (6) BZN—300 mg + E1224 for 8 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 8 weeks plus fosravuconazole and (7) Placebo: samples collected from individuals treated with Placebo. The proportions of patients were calculated at a log ratio threshold of the DF50 of −0.7.
Back to article page